Brii Biosciences enters a licensing agreement with Joincare Group for BRII-693 in Chinese markets
In a significant move to combat the growing threat of antimicrobial resistance, Brii Biosciences Limited and Joincare Pharmaceutical Group Industry Co., Ltd have entered into an exclusive licensing agreement for the development, regulatory approval, and commercialization of BRII-693 in Greater China.
BRII-693 is a novel synthetic lipopeptide antibiotic, designed to treat critically ill patients with multidrug- and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections. These infections include carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), and Enterobacterales (CRE), as mentioned in the agreement.
The partnership aims to deliver a critical care medicine to Chinese patients facing life-threatening infections. Joincare Group, with its proven capabilities in manufacturing and commercializing hospital antibiotics, was identified as the ideal partner for accelerating the development and commercialization of BRII-693.
BRII-693 has shown promising Phase 1 clinical results with favorable safety and tolerability in both Chinese and non-Chinese participants. Early data from the project shows encouraging results in terms of therapeutic potential, pharmacodynamics, and pharmacokinetics, suggesting its high potential to become a best-in-class therapy.
Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval, and commercialization of BRII-693 in Greater China. Brii Bio will receive an upfront payment, milestone payments linked to development and sales progress, and tiered royalties on net sales generated by Joincare.
Nanqi Lin, CEO of Joincare Group, emphasized the company's deep scientific expertise and robust R&D platform as key factors in their involvement with the BRII-693 project. The well-established R&D system of Brii Bio was a significant factor in the success of the BRII-693 project, as noted by Nanqi Lin.
Dr. Zhi Hong, Chairman and CEO of Brii Bio, expressed the urgency for novel hospital antibiotics in Greater China due to the growing threat of antimicrobial resistance. He expressed confidence in the clinical prospects of BRII-693 and looked forward to launching the asset soon, providing more high-quality treatment options for patients.
The agreement grants Joincare Group an exclusive license for the research, development, and commercialization of BRII-693 in the Greater China region. This partnership is intended to accelerate the path to market for BRII-693, addressing the urgent unmet need posed by antimicrobial resistance in the region.
Sources: [1] Brii Bio. (2022). Press Release: Brii Bio and Joincare Pharmaceutical Group Enter into Exclusive Licensing Agreement for BRII-693 in Greater China. Retrieved from https://www.briibio.com/news/press-releases/detail/2022/Brii-Bio-and-Joincare-Pharmaceutical-Group-Enter-into-Exclusive-Licensing-Agreement-for-BRII-693-in-Greater-China
[2] Joincare Pharmaceutical Group Industry Co., Ltd. (2022). Press Release: Joincare Pharmaceutical Group and Brii Bio Announce Exclusive Licensing Agreement for BRII-693 in Greater China. Retrieved from https://www.joincare.com/en/news/press-release/2022/Joincare-Pharmaceutical-Group-and-Brii-Bio-Announce-Exclusive-Licensing-Agreement-for-BRII-693-in-Greater-China
[3] National Medical Products Administration. (2022). Investigational New Drug (IND) Approval for BRII-693. Retrieved from https://www.nmpa.gov.cn/news_detail/9225.html
- The collaboration between Brii Bio and Joincare Pharmaceutical Group focuses on the development and commercialization of BRII-693, a potential treatment for life-threatening medical-conditions such as multidrug-resistant bacterial infections like carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), and Enterobacterales (CRE), which pose a significant threat to health-and-wellness.
- The partnership between Brii Bio and Joincare Pharmaceutical Group aims to deliver critically needed medicines to Chinese patients, leveraging Joincare's expertise in manufacturing and commercializing hospital antibiotics and Brii Bio's robust R&D platform, with the ultimate goal of advancing science and combatting antimicrobial resistance in the medical-conditions arena.
